3D-QSAR studies of various diaryl urea derivatives of multi-targeted receptor tyrosine kinase inhibitors: Molecular field analysis approach

Letters in Drug Design and Discovery

Volumn 5, Issue 7, 2008, Pages 437-448

  Kansal, Neha ^a   Silakari, Om ^a   Ravikumar, Muttineni ^b  

^a PUNJABI UNIVERSITY   (India)

^b GVK BIOSCIENCES PVT LTD   (India)

Author keywords

Genetic partial least squares (G PLS) method; MFA; Molecular field analysis; QSAR; Receptor tyrosine kinase

Indexed keywords

FLT3 LIGAND; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UREA DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG DESIGN; IC 50; MOLECULAR MODEL; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

EID: 53549101002     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018008785909868     Document Type: Article

References (25)

1. Shawver, L.K.; Lipson, K.E.; Fong, T.A.T.; McMahon, G.; Plowman, G.D.; Strawn, L.M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov. Today, 1997, 2, 50-63.
2. Risau, W. Mechanism of angiogenesis. Nature, 1997, 386, 671-674.
3. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
4. Zetter, B.R. Angiogenesis and tumor metastasis. Annu. Rev. Med., 1998, 49, 407-424.
5. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature, 2005, 438, 967-974.
6. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell, 1990, 61, 203-212.
7. Hubbard, S.R.; Till, J.H. Protein tyrosine kinases: structure and function Annu. Rev. Biochem., 2000, 69, 373-398.
8. Skobe, M.; Fusenig, N.E. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl Acad. Sci. USA, 1998, 95, 1050-1055.
9. Lindahl, P.; Johansson, B.R.; Leveen, P.; Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science, 1997, 277, 242-245.
10. Lin, E.Y.; Nguyen, A.V.; Russell, R.G.; Pollard, J.W. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193, 727-740.
11. Stirewalt, D.L.; Radich, J.P. The role of FLT3 in Haematopoietic malignancies. Nat. Rev. Cancer, 2003, 3, 650-665.
12. Demetri, G.D. Targeting c-Kit mutations in solid-tumors: scientific rationale and novel therapeutic options. Semin. Oncol., 2001, 28, 19-26.
13. Hopfinger, A.J.; Tokarsi, J.S.; Charifson, P.S. Practical Application of Computer - Aided Drug Design, Marcel Dekker: New York, 1997.
14. Dai, Y.; Hartandi, K.; Ji, Z.; Ahmed, A.A.; Albert, D.H.; Bauch, J.L.; Bouska, J.J.; Bousquet, P.F.; Cunha, G.A.; Glaser, K.B.; Harris, C.M.; Hickman, D.; Guo, J.; Li, J.; Marcotte, P.A.; Marsh, K.C.; Moskey, M.D.; Martin, R.L.; Olson, A.M.; Ostering, D.J.; Pease, L.J.; Soni, N.B.; Stewart, K.D.; Stoll, V.S.; Tapang, P.; Reuter, D.R.; Davidsen, S.K.; Michaelides, M.R. Discovery of N-(4-(3-amino-1-H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methyl- phenyl) urea (ABT-869), a 3-aminoindazole based orally active multitargeted receptor tyrosine kinase inhibitor. J. Med. Chem., 2007, 50, 1584-1597.
15. Dai, Y.; Hartandi, K.; Soni, N.B.; Pease, L.J.; Reuter, D.R.; Olson, A.M.; Osterling, D.J.; Doktor, S.Z.; Albert, D.H.; Bouska, J.J.; Glaser, K.B.; Marcotte, P.A.; Stewart, K.D.; Davidsen, S.K.; Michaelides, M.R. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 386-390.
16. Kolb, A.J.; Kaplita, P.V.; Hayes, D.J.; Park, Y.-W.; Pernell, C.; Major, J.S.; Mathis, G. Tyrosine kinase assays adapted to homogenous time-resolved fluorescence. Drug Disc. Tod., 1998, 3, 333-342.
17. 2 Molecular Modelling Program Package, Molecular Simulations (Accelrys) Inc.; San Diego, CA 92121-3752. USA, http://www.accelrys. com/cerius2.
18. Mayo, S.L.; Olafson, B.D.; Goddard, W.A. Dreiding: a generic force field for molecular simulations. J. Phys. Chem., 1990, 94, 8897-8909.
19. Rappe, A.K.; Goddard III, W.A. Charge equilibration method for molecular dynamics simulations. J. Pins. Chem., 1991, 95, 3358-3363.
20. Dewar, M.J.S.; Zoebisch, E.G.; Healy, E.F.; Stewart, J.J.P. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc., 1985, 107, 3902-3909.
21. Wold, S. In Chemometric Methods in Molecular Design; van de Waterbeemd, Ed.; VCH, Weinheim, 1995; Vol. 2, pp. 195-218.
22. Fan, Y.; Shi, L.M.; Kohn, K.W.; Pommier, Y.; Weinstein, J.N. Quantiataive structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithmbased studies. J. Med. Chem., 2001, 44, 3254-3263.
23. Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Mans, A.; Rognan, D. In 3D QSAR in Drug Design. Theory, Methods and Applications; Kubinyi, H. Ed.; ESCOM, Leiden, The Netherlands, 1993; pp. 711-716.
24. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches, VCH, Weinheim, 1993.
25. 2. J. Mol. Graph. Mod., 2002, 20, 269-276.